PACTR202310719625892尚未招募1 期
A phase 1, single-center, double-blind, randomized, placebo-controlled trial to assess the safety, tolerability and initial efficacy of AHC01 delivered via transcervical catheter in adult females (25-55 years), experiencing abnormal uterine bleeding and scheduled for a hysterectomy.
Avana Health0 个研究点目标入组 20 人开始时间: 2023年9月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 45 Year(s) 至 64 Year(s)（—）
- 性别
- Female
入选标准
- •1. Age between 25 and 55 years old, inclusive.
- •2. Have a history of the symptom of heavy menstrual bleeding presumed to be AUB-E, or AUB-LSM Type 4 tumors – less than 4 cm for a single myoma
- •3. Will have a history of cyclically predictable onset of menses every 24-38 days with no more than 9 days of variance (shortest to longest) in the past six months.
- •4. Are scheduled for a hysterectomy, or plans to have a hysterectomy in the next 60 days
- •5. Screening hemoglobin levels > 7.0 g/dL
- •6. Uterine ultrasound calculated uterine volume of = 30 mL
- •7. Negative serum pregnancy test at the Screening visit
- •8.Sexually active women agree to use an effective method of contraception throughout the course of the study. For this study, effective methods of contraception are considered to be: Barrier method, i.e., (a) condom (male or female) with spermicide or (b) diaphragm with spermicide; Vasectomy (partner); avoidance, if in line with the preferred and usual lifestyle of the subject [defined as refraining from heterosexual intercourse]
- •9. Demonstrates an understanding of how to record menstrual blood loss using a menstrual pictogram.
- •10. Provide voluntary written/thumb-printed informed consent.
- •11. Be willing to comply with study requirements and procedures and be willing and able to return for all scheduled follow-up visits.
- •12. In otherwise good health as determined by medical history and physical examination.
- •13. For the duration of the study, be willing to avoid medication not prescribed by the study team.
- •14. Have a readily identifiable place of residence identified on Google Maps.
- •15. Can limit travel outside the study area during the post-treatment period of study participation
- •At the end of the Qualification Phase, participants must meet all the following additional inclusion criteria to continue into the Treatment Phase (randomization and treatment):
- •16. Demonstrated baseline PBAC of >150.
- •17. Have demonstrable visible active bleeding at the time of treatment
排除标准
- •1. Currently on systemic therapy that alters endogenous gonadal steroid production. These include oral, transdermal, and transvaginal estrogen and progestin-containing contraceptives, oral or injectable progestins including depomedroxyprogesterone acetate (DMPA), and gonadotropin releasing hormone (GnRH) modulators including GnRH agonists and antagonists.
- •2. Current use of tranexamic acid (eg Lysteda®)
- •3. Less than 12 months since the last use of DMPA.
- •4. Less than 6 months since the last use of oral, transdermal or transvaginal hormonal agents, including oral GnRH antagonists.
- •5. Less than 9 months since the last injection of depot leuprolide acetate (Depolupron®) 11.25 mg (other formulations will depend on the dose).
- •6. Has a progestin-releasing intrauterine system (IUS) (Mirena® or other), OR less than 6 months since removal of such a device.
- •7. Underwent prior uterine surgery that interrupts the integrity of the myometrium (e.g., transmural myomectomy, classical Cesarean section, endometrial ablation (by any technique), hysteroscopic myomectomy).
- •8. Endometrial curettage (D&C) in the last 3 months.
- •9. Endometrial biopsy in the last 3 months.
- •10. Presence of bacteremia, sepsis, or other active systemic infection
- •11. Previous gynecological malignancy including, not limited to vaginal, cervical, endometrial, fallopian tube, and ovarian cancer. This does NOT include cervical intraepithelial neoplasia (CIN), but DOES INCLUDE atypical endometrial hyperplasia, also known as endometrial intraepithelial neoplasia (EIN).
- •12. Individuals who have known submucous leiomyomas, specifically excluding those with AUB-LSM meaning those with FIGO Types 0, 1, 2.
- •13. Individuals with AUB-LSM Type 4 tumors – greater than 4 cm for a single myoma
- •14. Individuals who have known uterine adenomyosis
- •15. Post-partum = 6-months
- •16. Breastfeeding in the past six months
- •17. Currently using anticoagulant treatment
- •18. Have used any other investigational product within 90 days prior to randomiz
研究者
相似试验
已完成
不适用
A Phase I, single*center, double-blind, randomized, placebo-controlled, single and multiple ascending dose trial to evaluate the safety and pharmacokinetics of PTC857 in healthy volunteers.10007951Parkinson's DiseaseNL-OMON49571PTC Therapeutics, Inc.82
已完成
1 期
A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of ascending multiple oral doses of XW10172 in healthy adult subjectsarcolepsyNarcolepsyInflammatory and Immune System - Autoimmune diseasesNeurological - Other neurological disordersACTRN12618001038280XW Laboratories (Australia) Pty Ltd24
已完成
1 期
A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of ascending single oral doses of XW10172 in healthy adult subjectsACTRN12618000127202XW Laboratories (Australia) Pty Ltd50
已完成
不适用
A phase 1, single center, randomized, double-blind, placebo-controlled, single (Part 1) and multiple (Part 2) ascending dose study to evaluate the safety,tolerability, pharmacokinetics and pharmacodynamics of M281 administered to healthy volunteers.auto-immuunziekten en ontstekingsziekten.autoimmune diseases and inflammatory diseasesNL-OMON43123Momenta Pharmaceuticals, Inc.74
尚未招募
不适用
A single-center, double-blind, randomized, phase I/II dose escalating study to assess the safety, tolerability and immunogenicity of three doses of the therapeutic synthetic long peptide (SLP) vaccine (ISA104) in patients with chronic hepatitis B (cHBV).chronic hepatitis BcHBV10047438NL-OMON51362Erasmus MC, Universitair Medisch Centrum Rotterdam24